A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
Số trang: 9
Loại file: pdf
Dung lượng: 616.66 KB
Lượt xem: 10
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that lack of effective therapeutic drugs. K-001 is an oral antitumor drug made from active ingredients of marine microorganisms. The current study aimed to evaluate safety and antitumor activity of K-001 in patients with advanced PDAC.
Nội dung trích xuất từ tài liệu:
A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
Nội dung trích xuất từ tài liệu:
A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Pancreatic ductal adenocarcinoma Phase I study Clinical trial Dose-limiting toxicityTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 173 0 0 -
6 trang 168 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 145 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 121 0 0 -
12 trang 94 0 0
-
19 trang 75 0 0
-
17 trang 65 0 0
-
9 trang 45 0 0
-
12 trang 39 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0